Abstract Library

#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hernando-Cubero J

Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,

Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,

#1392 How Long Should We Look Up for Recurrence After Resection of Pancreatic Neuroendocrine Tumors?

Introduction: There remains several unsolved issues to be settled about the management of pancreatic neuroendocrine tumors (PNETs) after resection. One of these problems are the follow up period after a complete resection of the tumor.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Sato A, Masui T, Nakano K, Kawaguchi Y, Takaori K,

Keywords: Pancreatic neuroendocrine tumor, enucleation, follow-up period,

#184 Somatostatin Analogues as a Therapeutic Option in a Series of 91 Patients with Gastric Carcinoids

Introduction: Gastric carcinoid tumors (GC) represent about 10-30% of carcinoid tumors and about 1% of all stomach neoplasms. They include three types : type 1 (70-85%), type 2 (5-10%) and type 3 (15-25%).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Basagiannis C, Angelopoulos T, Papadimitriou C, Geragotou T, Siakavellas S,

Keywords: gastric carcinoid, gastrin, Somatostatin analogues.,

#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors

Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Kanakis G, Antonioy S, Thomas D, Zilos A, Roussaki P,

Keywords: neuroendocrine tumors, adrenal incidentalomas, staging,

#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Hess G, Hill J, Chen C, Quigley J, Liu Z,

Keywords: neuroendocrine tumors, clinical characteristics, demographic characteristics,